Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | MAT2A | P31153 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005879 | 0.82 | PIM1 (0.48) | SMN1; SMN2MAPTCNR1PRKCBPRKCA | |
| Acetic Acid SCHEMBL7011660 | 0.80 | CAMK2D (0.46) | SMN1; SMN2MAPTCNR1PRKCBPRKCA | |
| SCHEMBL8159852 | 0.72 | ALDH1A1 (0.46) | ALDH1A1GAAHPGDNPC1SMN1; SMN2 | |
| SCHEMBL3493089 | 0.71 | ALDH1A1 (0.45) | ALDH1A1GAAHPGDNPC1SMN1; SMN2 | |
| SCHEMBL3494243 | 0.69 | ALDH1A1 (0.47) | PKMALDH1A1GAAHPGDSMN1; SMN2 | |
| SCHEMBL6379635 | 0.69 | NR4A2 (0.69) | ALDH1A1MAPTNPSR1CNR1KDM4E | |
| SCHEMBL8238381 | 0.68 | PDE4A (0.40) | ALDH1A1GAAHPGDNPC1SMN1; SMN2 | |
| SCHEMBL885461 | 0.68 | MAT2A (0.53) | ALDH1A1GAAHPGDNPC1SMN1; SMN2 | |
| SCHEMBL3493465 | 0.67 | ALDH1A1 (0.45) | ALDH1A1GAASMN1; SMN2MAPTNPSR1 | |
| SCHEMBL7008865 | 0.67 | PIM1 (0.40) | CCNE2CDK4CCND1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042317-B1 | Indole derivatives as PKC-inhiboitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | claimed |
| US-6337342-B1 | ARYLIMIDAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | claimed |
| EP-1042317-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032483-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | claimed |
| US-20030134886-A1 | Pharmaceutically active compounds | ASTRAZENECA AB, A SWEDISH CORPORATION | 2003-07-17 | — | — | US | disclosed |
| EP-1042317-B1 | Indole derivatives as PKC-inhiboitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| US-6492409-B1 | SUCH AS 5-(1-(3-AMINOPROPYL)-3-INDOLYL)-1-(3-INDOLYL)-1,3-DIHYDROIMIDAZOL-2-ONE; PROTEIN KINASE C INHIBITORS; HIGH SOLUBILITY; REDUCED COLOR; TREATING INFLAMMATORY AND/OR IMMUNOLOGICAL DISORDERS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1192150-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2002-04-03 | — | — | EP | disclosed |
| US-6337342-B1 | ARYLIMIDAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| WO-2000078750-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134886-A1 | Pharmaceutically active compounds | HTR3C, HTR6, CNR1 | PKM 2899/4885ALDH1A1 606/4885GAA 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.